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Abstract
Background: Mesenchymal stem cells (MSCs) are a heterogeneous subset of stromal cells currently tested for
multiple therapeutic purposes. Their potential to home into tumors, to secrete trophic/vasculogenic factors, and to
suppress immune response raises questions regarding their biosafety. Our aim was to evaluate whether systemically
administered allogeneic MSCs modify the natural progression of precancerous lesions and whether their putative
effect depends on cancer stage and/or cell dose.
Methods: Oral squamous cell carcinoma (OSCC) was induced in Syrian golden hamsters by topical application of
7,12-dimethylbenz[a]anthracene in one buccal pouch. At hyperplasia, dysplasia, or papilloma stage, animals received
intracardially the vehicle or 0.7 × 106, 7 × 106, or 21 × 106 allogeneic bone marrow-derived MSCs/kg. OSCC
progression was assessed according to the presence of erythroplakia and leukoplakia, extent of inflammation and
vascularization, and appearance, volume, and staging of tumors. Also, the homing of donor cells was studied.
Results: Precancerous lesions progressed from hyperplasia to dysplasia in 2 weeks, from dysplasia to papilloma
in 3 weeks, and from papilloma to carcinoma in 4 weeks. This time course was unmodified by the systemic
administration of MSCs at hyperplasia or dysplasia stages. When MSCs were administered at papilloma stage,
lesions did not progress to carcinoma stage. Tumors developed in hamsters receiving 0.7 × 106 or 7 × 106 MSCs/kg
at hyperplasia stage were significantly smaller than those found in control animals (25 ± 4 or 23 ± 4 mm3 versus
72 ± 19 mm3, p < 0.05). Similar results were obtained when 0.7 × 106, 7 × 106, or 21 × 106 MSCs/kg were administered
at papilloma stage (44 ± 15, 28 ± 7, or 28 ± 5 mm3 versus 104 ± 26 mm3, p < 0.05). For dysplasia stage, only the lower
concentration of MSCs reached statistical significance (21 ± 9 mm3 versus 94 ± 39 mm3, p < 0.05). Animals receiving
21 × 106 MSCs/kg at hyperplasia stage developed tumors larger than those found in animals that received the vehicle
(147 ± 47 mm3 versus 72 ± 19 mm3, p < 0.05). Donor cells were rarely found in precancerous lesions.
Conclusions: Systemically administered allogeneic MSCs do not aggravate the progression of precancerous lesions.
Moreover, they preclude cancer progression and tumor growth.
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Background
Mesenchymal stem cells (MSCs) are self-renewable undif-
ferentiated cells found in almost all adult tissues [1]. MSCs
can be procured from living donors, can be efficiently ex-
panded ex vivo [2], are hypoimmunogenic so a condition-
ing regimen is not required before their transplantation
[3], home into injured tissues and tumors [4, 5], differenti-
ate into tissue cells [6], secrete trophic factors [7], pro-
mote neovascularization [8], reduce oxidative stress [9],
and modulate the immune response [10]. Thus, MSCs
appear to be an ideal tool for cell-based therapies.
The number of people receiving MSCs worldwide is
increasing [11]. Some of them are patients enrolled in
clinical trials but many of them receive the cells in the
context of commercial unproved medical or cosmetic of-
fers. Results of clinical trials are promising, nonetheless
safety issues regarding MSC-based therapies are still un-
proven [12].
Currently, the envisioned adverse effects related to
MSC administration are embolization, acute or chronic
rejection, zoonosis when animal-derived products are
used for cell expansion, increased susceptibility to infec-
tions, or upcoming neoplasia [13, 14]. A systematic re-
view of 36 clinical trials showed no association between
the intravascular administration of MSCs and acute tox-
icity, organ complications, infections, or de-novo malig-
nancies [15]. Paradoxically, in animal models it has been
shown that MSCs have both antitumor and protumor ef-
fects [14, 16]. Discrepancies have been explained by the
source, dose, or delivery route, and also by the type and
stage of cancer.
In order to fulfill a conclusive safety profile of MSCs,
large-scale controlled studies with longer follow-up of
adverse events are indispensable. Together, novel bio-
safety concerns should be studied systematically. One of
these is the impact of MSC administration on the pro-
gression of precancerous lesions. These lesions are
underdiagnosed and precede skin, oral cavity, esophagus,
lung, pancreas, bladder, gallbladder, breast, ovary, cervix,
and prostate cancers [17].
The aim of our work was to evaluate whether system-
ically administered allogeneic MSCs modify the natural
progression of precancerous lesions and whether their
putative effect depends on cancer stage and/or cell dose.
For this, we used a preclinical model of oral squamous
cell carcinoma (OSCC) that reproduces the etiology, ma-




OSCC was induced in one buccal pouch of adult male
hamsters. At hyperplasia, dysplasia, or papilloma stage,
animals received intracardially the vehicle or 0.7 × 106,
7 × 106, or 21 × 106 allogeneic bone marrow-derived
MSCs/kg (Fig. 1). Every week, buccal pouches were
assessed macroscopically. At the end of the study period
(13 weeks), tumors were analyzed microscopically. For
each stage, the homing of donor cells into precancerous
lesions was evaluated 1 day after MSC administration.
The protocol was approved by the Ethic Committee of
Facultad de Medicina Clinica Alemana-Universidad del
Desarrollo (approval ID: 2011-14).
Animals
A total of 270 Syrian golden hamsters (Mesocricetus aur-
atus) were used in this study: 90 served as MSC donors
and 180 were OSCC induced (60 hyperplasia, 60 dyspla-
sia, 60 papilloma). Animals were housed at 22 °C, con-
stant humidity, with a 12 h:12 h light–dark cycle, and
food and water ad libitum. Hamsters were anesthetized
by intraperitoneal injection of 20 mg/kg xylazine
(Centrovet, Chile) and 200 mg/kg ketamine (Ilium,
Argentina), and were euthanized by intraperitoneal in-
jection of 40 mg/kg xylazine and 400 mg/kg ketamine.
To regulate respiratory frequency during anesthesia, ani-
mals received sublingually 0.2 mg Viviram-V (Holliday
Scott, Mexico).
Induction of OSCC
Healthy male hamsters, 8 weeks old, weighing 142 ± 17 g,
were painted three times a week in their right buccal
pouch with a No. 4 camel-hair brush soaked with 50 μl of
0.5% (w/v) dimethylbenz[a]anthracene (DMBA) (Sigma-
Aldrich, St. Louis, MO, USA) dissolved in mineral oil
(Sigma-Aldrich) [18].
Isolation, ex-vivo expansion, and characterization of MSCs
Healthy female hamsters, 8 weeks old, were euthanized
and femurs and tibias were procured under sterile con-
ditions. The epiphyses were removed and bone marrow
cells were collected by flushing bones with sterile phos-
phate buffer saline (Gibco, Auckland, New Zealand). Re-
covered cells were resuspended in alpha-MEM (Gibco)
supplemented with 10% fetal bovine serum (Gibco) and
80 μg/ml gentamycin (Sanderson Laboratory, Chile), and
plated at a density of 0.25 × 106 nucleated cells/cm2 in
plastic tissue-culture dishes. After 72 h, nonadherent
cells were removed by medium change. When foci
reached confluence, adherent cells were detached with
0.25% trypsin, 2.65 mM EDTA (Gibco) and subcultured.
At 70–80% confluence, cells were tripsinized, centrifuged,
resuspended in alpha-MEM, counted, characterized,
and injected.
Cell immunophenotyping was performed by flow cytom-
etry after immunostaining with APC-conjugated anti-
CD45 (BD Pharmingen, USA), FITC-conjugated anti-alpha
smooth muscle actin (Sigma), and FITC-conjugated mouse
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anti-vimentin (Oncogen, USA) [2]. To assess differenti-
ation potentials, cells were incubated with adipogenic or
osteogenic induction media [20]. Seven and 14 days later,
samples were stained with Oil Red O or Alizarin Red
(Sigma) (Additional file 1: Figure S1).
Systemic administration of MSCs
When the target OSCC stage was reached, animals were
distributed randomly among the experimental groups.
After anesthesia, the heart was palpated and the needle
of a Tuberculin syringe (Terumo, Japan) was inserted at ster-
num height [21]. Once retrograde flow was observed, 600 μl
of 5% hamster plasma in physiological serum (vehicle)
or 0.1 × 106, 1 × 106, or 3 × 106 MSCs resuspended in
the vehicle were injected. These numbers of cells results in
doses of 0.7 × 106, 7 × 106, or 21 × 106 MSCs/kg, respectively.
Macroscopic assessment of OSCC stages
Four, 6, 9, and 13 weeks after the first DMBA exposure,
animals were anesthetized and the right buccal pouch
Fig. 1 Study design. Syrian golden hamsters, male, 8 weeks old, were exposed to 7,12-dimethylbenz[a]anthracene (DMBA) three times a week. At
hyperplasia, dysplasia, or papilloma stage, animals were randomized among experimental groups and received intracardially vehicle or 0.7 × 106, 7 × 106,
or 21 × 106 mesenchymal stem cells (MSCs)/kg. Every week, buccal pouches were assessed macroscopically. At the end of study period (13 weeks),
tumors were analyzed microscopically. For each stage, homing of donor cells into precancerous lesions was evaluated 1 day after MSC administration
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was exposed and photographed using a digital camera
(FUJIFILM-Finepi HS20 EXR or Olympus SP5 10). Two
independent observers analyzed the photographs and
classified lesions according to the absence/presence of
erythroplakia, leukoplakia, inflammation, vascularization,
ulcers, or exophytic nodules [18]. Tumors were measured
with a digital caliper (Mitutoyo Sul Americana, Brazil).
The tumor volume was calculated using the formula: tumor
volume (mm3) = 0.52 ×width (mm)2 × length (mm) [22].
Microscopic assessment of OSCC stages
Thirteen weeks after the first DMBA exposure, animals
were euthanized, right buccal pouches were procured, and
tumors were resected. Samples were fixed in 10% buffered
formalin (Merck, USA), embedded in paraffin (Merck),
and sectioned. Tissue sections of 4 μm were deparaffinized
with Neoclear (Merck), rehydrated with graded alcohols,
stained with hematoxylin–eosin (Merck), and visualized
with a light microscope (DM2000; Leica, Germany). Im-
ages were captured with a digital camera (DFC295; Leica).
Samples were classified as hyperplasia, dysplasia, papil-
loma, or carcinoma as described previously [18, 19].
Histological analyses were performed blind by three
independent observers; one of them is a pathologist
expert in oral diseases.
Detection of donor MSCs in recipient mucosa
MSCs were labeled with 25 μM CellTracker Red
CMTPX (Invitrogen, USA) for 20 min at 37 °C. After
washing, cells were tripsinized and injected intracardially
(see earlier). The day after, hamsters were euthanized,
and buccal pouches were procured and fixed with OCT
(Tissue-Teck, USA). Cryosections of 10 μm thickness
were stained with DAPI (Invitrogen, USA), mounted
with epifluorescence medium (Dako, USA), and visual-
ized with an epifluorescence microscope (DM2000
(Leica) or Flv10i.doc (Olympus, USA)) [6].
Statistical analysis
As data distribution was nonparametric, results were
presented as median ± SEM. Tumor volume com-
parisons were performed using one-way ANOVA test
followed by Dunn’s post test. Statistical analyses were
performed using StatGraph Prism 5.0 software. p < 0.05
with a confidence interval of 95% was considered statis-
tically significant.
Results
Systemically administered allogeneic MSCs do not
accelerate the progression of precancerous lesions
Four weeks after the first DMBA exposure, buccal
pouches of animals that received the vehicle were
retracted, and erythroplakia, leukoplakia, or both were
evident (Fig. 2). Together, an engrossment of the mucosa
due to inflammation was observed. Two weeks later
(6 weeks after the first DMBA exposure), mucosa
engrossed and lost elasticity; no tumors were visible
at this time point. Three weeks later (9 weeks after
the first DMBA exposure), exophytic lesions pro-
truded from the surface and therefore tumors were
measurable. Four weeks later (13 weeks after the first
DMBA exposure), buccal pouches retracted and stiffened,
presenting features of necrosis and larger tumors. This
time course was unchanged in animals receiving MSCs at
hyperplasia (Fig. 2) or dysplasia (Fig. 3) stage. At week 13,
the buccal pouches of animals receiving MSCs at papil-
loma stage neither retracted nor presented features of
necrosis (Fig. 4). Also, tumors did not enlarge.
Systemically administered allogeneic MSCs do not
increase tumor malignancy
Thirteen weeks after the first DMBA exposure, the oral
mucosa of animals receiving the vehicle showed cell and
nuclear pleomorphism, the epithelium stratification was
lost, the basal membrane appeared discontinuous, ves-
sels were aberrant (large size and discontinuous wall),
and inflammatory foci were abundant (Figs. 5, 6, and 7).
Therefore, at the end of the study period all animals re-
ceiving the vehicle presented carcinoma. The same was
observed in hamsters receiving MSCs at hyperplasia
stage (Fig. 5). For animals that received 0.7 × 106, 7 × 106,
or 21 × 106 MSCs/kg at dysplasia stage, the frequencies of
lesions that progressed to carcinoma were 67, 66, and
90%, respectively (Fig. 6). When MSC administration was
performed at papilloma stage, the frequencies of malignant
transformation were 27, 13, and 10% for 0.7 × 106, 7 × 106,
or 21 × 106 MSCs/kg, respectively (Fig. 7). Most of the
tumors found in animals receiving MSCs at papilloma
stage remained at this stage, and showed continuous basal
membrane and rare epithelial cells invading the stroma.
Low doses of systemically administered allogeneic MSCs
preclude OSCC tumor growth
Thirteen weeks after the first DMBA exposure, the mean
size of tumors developed in animals receiving the vehicle at
hyperplasia, dysplasia, or papilloma stage was 90 ± 28 mm3
(72 ± 19 mm, 94 ± 39 mm, and 104 ± 26 mm, respectively)
(Fig. 8). The administration of 0.7 × 106 or 7 × 106 MSCs/kg
at hyperplasia stage resulted in tumors three times smaller
(25 ± 4 mm3 or 23 ± 4 mm3). However, the high dose of
MSCs resulted in tumors two times bigger (147 ± 47 mm3).
All of the observed differences were statistically significant
(p < 0.05) (Fig. 8). When MSCs were administered at
dysplasia stage, no difference was observed when compared
with the control, except for the low dose (21 ± 9 mm3;
p < 0.05). Animals that received MSCs at papilloma
stage developed tumors two to three times smaller than
those presented in control animals (0.7 × 106 MSCs/kg,
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Fig. 2 Systemically administered allogeneic MSCs do not accelerate progression of precancerous lesions. At hyperplasia stage, hamsters received
intracardially vehicle or 0.7 × 106, 7 × 106, or 21 × 106 MSCs/kg. Progression of precancerous lesions was assessed macroscopically (n = 14). MSC
mesenchymal stem cell
Fig. 3 Systemically administered allogeneic MSCs do not accelerate progression of precancerous lesions. At dysplasia stage, hamsters received
intracardially vehicle or 0.7 × 106, 7 × 106, or 21 × 106 MSCs/kg. Progression of precancerous lesions was assessed macroscopically (n = 14). MSC
mesenchymal stem cell
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Fig. 4 Systemically administered allogeneic MSCs do not accelerate progression of precancerous lesions. At papilloma stage, hamsters received
intracardially vehicle or 0.7 × 106, 7 × 106, or 21 × 106 MSCs/kg. Progression of precancerous lesions was assessed macroscopically (n = 14). MSC
mesenchymal stem cell
Fig. 5 Systemically administered allogeneic MSCs do not increase tumor malignancy. At hyperplasia stage, hamsters received intracardially vehicle
or 0.7 × 106, 7 × 106, or 21 × 106 MSCs/kg. At end of study period (13 weeks), tumors were assessed microscopically. Stage frequency
was calculated for each group. Bar = 100 μm (number of replicates = 6, n = 14). MSC mesenchymal stem cell
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44 ± 15 mm3; 7 × 106 MSCs/kg, 28 ± 7 mm3; 21 × 106
MSCs/kg, 28 ± 5 mm3; p < 0.05 for the three comparisons).
Systemically administered allogeneic MSCs rarely home
into precancerous lesions
One day after intracardial administration, MSCs labeled
with CMTPX (donor cells) were scarcely found in the
oral mucosa of animals presenting precancerous lesions at
dysplasia or papilloma stage, but not at hyperplasia stage
(Fig. 9). Since not all of the sections analyzed presented
donor cells and the number of donor was very low
(1–3 cells/field), quantitative analysis was not performed.
Discussion
In this study, we present evidence in support of the
hypothesis that systemically administered allogeneic
MSCs neither accelerate the progression nor increase
tumor malignancy of precancerous lesions. Moreover,
we show that depending on the stage of the precancer-
ous lesion and the dose of cells, the systemic administra-
tion of allogeneic MSCs precludes OSCC progression
and tumor growth. To our knowledge, these observa-
tions are without precedent since the antitumor effect
already described for systemically administered MSCs
has been proven in animal models bearing preestab-
lished tumors or receiving tumor cells together with the
MSCs [23, 24].
The fact that systemically administered allogeneic
MSCs do not aggravate the progression of precancerous
lesions is a relevant safety outcome. Due to its simplicity
and the ability of MSCs to home into injured tissues,
intravenous injection is the preferred route in currently
proposed MSC-based therapies. Most frequent malig-
nancies arise from precancerous lesions, which are
asymptomatic and underdiagnosed [25, 26]. Thus, there
is a high probability that candidate patients for MSC-
based therapies carry precancerous lesions, unnoticed by
themselves and by clinicians. Here, we provide empirical
evidence that this would not be a major health risk.
Regarding the beneficial effects of the systemic admin-
istration of MSCs, we observed a deterrence of OSCC
progression when cells were injected at dysplasia or
Fig. 6 Systemically administered allogeneic MSCs do not increase tumor malignancy. At dysplasia stage, hamsters received intracardially vehicle
or 0.7 × 106, 7 × 106, or 21 × 106 MSCs/kg. At end of study period (13 weeks), tumors were assessed microscopically. Stage frequency was
calculated for each group. Bar = 100 μm (number of replicates = 6, n = 14). MSC mesenchymal stem cell
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Fig. 7 Systemically administered allogeneic MSCs do not increase tumor malignancy. At papilloma stage, hamsters received intracardially vehicle
or 0.7 × 106, 7 × 106, or 21 × 106 MSCs/kg. At end of study period (13 weeks), tumors were assessed microscopically. Stage frequency
was calculated for each group. Bar = 100 μm (number of replicates = 6, n = 14). MSC mesenchymal stem cell
Fig. 8 Low doses of systemically administered allogeneic MSCs preclude OSCC tumor growth. At hyperplasia, dysplasia, or papilloma stage,
hamsters received intracardially vehicle or 0.7 × 106, 7 × 106, or 21 × 106 MSCs/kg. At end of study period (13 weeks), tumor volume was assessed.
(number of replicates = 2, n = 14). MSC mesenchymal stem cell
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papilloma stage but not at hyperplasia stage. Precancer-
ous lesions at advanced stages presented chronic inflam-
mation [27]. Thus, only at later stages might MSCs exert
their immunomodulatory effect impairing cancer pro-
gression [28]. Since our study design lasted up to a fixed
time point (13 weeks), we do not know whether this is a
delay or suppression of OSCC progression. Prolonged
follow-up is required to address this point.
The preclusion of OSCC tumor growth was observed ir-
respective of the stage of precancerous lesion but varied ac-
cording to the number of cells injected. The dose-
dependent effect of MSCs has also been proven in other
sceneries. In an ovine model of myocardial infarction it has
been shown that the low doses (25 × 106 or 75 × 106 MSCs)
but not the high ones (225 × 106 or 450 × 106 MSCs)
attenuated infarct expansion and preserved cardiac
function [29]. When the safety and efficacy of 20 × 106,
100 × 106, or 200 × 106 MSCs were tested in patients with
ischemic cardiomyopathy, the greatest effect in functional
capacity was reached with the low dose of cells [30].
The improvement of fistula healing was observed
when 30 × 106 MSCs were administered to patients
with Crohn’s disease, but not when the dose was
90 × 106 MSCs [31]. In all of these studies, the higher
doses of MSCs were less effective or have no effect.
In our study, the high dose of MSCs administered at
hyperplasia stage resulted in an undesirable effect
(bigger tumors). This could be explained by the fact that
the administration of a large number of cells in a barely
unhealthy animal might trigger an immune response
against the donor cells, resulting in their deactivation or
elimination, and/or might promote a long-term immuno-
suppression that facilitates posterior tumor growth [32].
As tumor growth restriction was not an expected out-
come of the present work, our original study design did
not consider exploration of the putative mechanisms be-
hind it. Previously, we showed that local administration of
allogeneic MSCs at dysplasia or papilloma stage precludes
OSCC tumor growth (unpublished results, [19]). While at
dysplasia stage MSCs impede mast cell infiltration and
diminish tissue vascularization, at papilloma stage donor
cells diminish proliferation, increase apoptosis, and reduce
epithelial dedifferentiation. Thus, the cellular conse-
quences of MSC administration vary according to the
stage of precancerous lesion. Here, we observed that sys-
temically administered allogeneic MSCs rarely home into
precancerous lesions since we hypothesize that beneficial
effects are due to systemic changes, as described for
diseases like autoimmune encephalomyelitis or type 1
diabetes mellitus [10, 33].
Although the limitation of our work is that results
were obtained in an animal model for one type of cancer,
the study represents a new biosafety insight for MSC-
based cell therapy. Also, it is a first approach to the use
of MSCs for the prevention of OSCC.
Conclusions
Systemically administered allogeneic MSCs do not aggra-
vate the progression of precancerous lesions. Moreover,
they preclude cancer progression and tumor growth.
Additional file
Additional file 1: Figure S1. Characterization of MSCs isolated from
bone marrow of Syrian golden hamster. Immunophenotype (a) and
differentiation potential (b). Dashed line, mean fluorescence intensity of
isotype control. Bar = 100 μm (n = 4). (TIF 1623 kb)
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